These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21808149)

  • 1. The obviousness rejection as a barrier to vaccine patent prosecution.
    Wang SJ
    Hum Vaccin; 2011 Apr; 7(4):474-6. PubMed ID: 21808149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.
    Lin F; Wang SJ
    Hum Vaccin Immunother; 2013 Nov; 9(11):2490-5. PubMed ID: 23899509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA patentability--anything but obvious.
    Dillen JS
    Wis L Rev; 1997; 5():1023-46. PubMed ID: 16329221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The written description rejection as a barrier to biotech patent prosecution.
    Wang SJ
    Hum Vaccin; 2011 May; 7(5):569-73. PubMed ID: 21552000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
    Pillai X; Kinney WA
    Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation.
    Dhulap S; Kulkarni M
    Pharm Pat Anal; 2019 Jul; 8(4):91-107. PubMed ID: 31414965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision.
    Dhulap S; Kulkarni MG
    Expert Opin Ther Pat; 2021 Oct; 31(10):951-963. PubMed ID: 33993810
    [No Abstract]   [Full Text] [Related]  

  • 8. Candida vaccines development from point view of US patent application.
    Wang SJ
    Hum Vaccin; 2011 Nov; 7(11):1165-71. PubMed ID: 22048114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KSR v. Teleflex. Part 1: Impact of U.S Supreme Court Patent Law on Canadian intellectual property and regulatory rights landscape.
    Bouchard RA
    Health Law J; 2007; 15():221-46. PubMed ID: 19702184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patenting DNA.
    Bobrow M; Thomas S
    Curr Opin Mol Ther; 2002 Dec; 4(6):542-7. PubMed ID: 12596355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The limited benefit of "product-by-process" claim.
    Chang BC; Wang SJ
    Hum Vaccin Immunother; 2016 Oct; 12(10):2685-2687. PubMed ID: 27441574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patent prosecution at the European Patent Office: what is new for life sciences applicants?
    Lidén C; Setréus E
    Expert Opin Ther Pat; 2011 Jun; 21(6):813-7. PubMed ID: 21457106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Something more is necessary: are genes and genetic diagnostic tests statutory subject matter for US patents?
    Cockbain J; Sterckx S
    Expert Rev Mol Diagn; 2011 Mar; 11(2):149-58. PubMed ID: 21405966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patentability of genes: a European Union perspective.
    Cole P
    Cold Spring Harb Perspect Med; 2014 Oct; 5(5):a020891. PubMed ID: 25324232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "real world" barriers and solutions to Candida vaccine patent prosecutions: an analysis of U.S. Patent and Trademark Office actions on related applications.
    Wang SJ
    Hum Vaccin Immunother; 2012 Oct; 8(10):1443-9. PubMed ID: 22894949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competition policy in patent cases and antitrust.
    Sobel G
    Adv Genet; 2003; 50():23-64; discussion 507-10. PubMed ID: 14714685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invisible genomes: the genomics revolution and patenting practice.
    Bostanci A; Calvert J
    Stud Hist Philos Biol Biomed Sci; 2008 Mar; 39(1):109-19. PubMed ID: 18331958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drafting eligible biotech and immunotherapy claims.
    Wang SJ
    Hum Vaccin Immunother; 2019; 15(11):2706-2712. PubMed ID: 30991887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Reference composition' not 'lead compound': recent developments in case law for obviousness of pharmaceutical composition claims.
    Highlander SL; Voges MH
    Pharm Pat Anal; 2012 Sep; 1(4):385-92. PubMed ID: 24236877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.